2025-07-23 07:48
publication
2025-07-23 07:48
Synektik accepted the company's division plan into two independent entities; Syn2Bio's newly created company will be separated related to research on new pharmaceutical molecules – Synektik said in a press release.
The remaining activity will remain in Sneaktik, and both companies will be listed on the WSE.
“Acceptance of the division plan is an important step introducing us to the planned division of Synektik into two independent companies, conducting different activities and attracting investors with different profiles and 'risk -at -risk'. Transfer to the son2bio activities related to research on new pharmaceutical molecules, including a card sources of their financing, “said the company's president, Cezary Kozanecki, quoted in a press release.
“In turn, the Synektik, whose results have previously been charged with the costs of these studies, will allow to achieve higher profitability and pay higher dividends. The separation of the current, diverse activity to independent companies will also allow investors for a separate, reliable valuation, taking into account the potential of each of them. We are convinced that it will lead to an increase in the value of both companies” – he added.
As indicated, another important stage of the process aimed at dividing Synektik will be the preparation of the prospectus by the Son2Bio, and then obtaining his approval by the Polish Financial Supervision Authority in connection with the planned issue of Son2Bio division actions, which will be assigned to Sneaktik's shareholders.
“Our intention is to finish this stage at the beginning of 2026, which will allow us to finalize the division and introduce the new company's shares on the WSE in the first half of next year,” said Kozanecki.
For the purposes of the planned division of Synektik, the company was valued, including activities released to the Son2Bio. It was prepared by an independent entity – minestment banking.
On June 30, 2025, the value of the entire Synektik was set at around PLN 2.11 billion (PLN 247.54 per share), of which the value of the transferred assets is about PLN 163 million (PLN 19.14 per share), i.e. about 7.73 percent. whole.
The valuation of activities released to the Son2Bio was made by the method of corrected net assets, taking into account the value of the previously incurred and part of the planned expenditure on research projects. On the other hand, when the valuation of the Synektik (without secreted activities), the method of discounted cash flows (DCF) and the comparative method were used.
As part of the Synektik's planned division to shareholders, Syn2Bio shares will be assigned in a ratio of 1 to 1. This means that for each action of Synektik owned in the so -called Reference day, the investor will receive one Son2Bio action.
The reference day will be appointed by KDPW, after approval of the Prospectus Son2Bio by the PFSA. After the last session, at which it will be possible to purchase Synektik's shares entitling to participate in the division (i.e. two working days before a fixed reference day), the reference rate for the next session will be reduced by the value of activities released to the Son2Bio (i.e. by about 7.73 percent). This value will also be a reference course for the first session of Syn2Bio shares on the WSE. (PAP Biznes)
mcb/ gor/
